Cargando…
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
OBJECTIVE: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site. METHODS: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking...
Autores principales: | Shi, Yuankai, Han, Ying, Yang, Jianliang, Liu, Peng, He, Xiaohui, Zhang, Changgong, Zhou, Shengyu, Zhou, Liqiang, Qin, Yan, Song, Yongwen, Liu, Yueping, Wang, Shulian, Jin, Jing, Gui, Lin, Sun, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587/ https://www.ncbi.nlm.nih.gov/pubmed/30996573 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10 |
Ejemplares similares
-
Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020) -
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022) -
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
por: Huang, Yu, et al.
Publicado: (2017) -
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
por: Chen, Haizhu, et al.
Publicado: (2022) -
Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
por: Wang, Qin, et al.
Publicado: (2016)